These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 15608078)
41. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain. Sadek B; Elz S; Pertz HH; Stark H; Schunack W Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060 [TBL] [Abstract][Full Text] [Related]
42. Guanosine 5'-(gamma-[35S]thio)triphosphate autoradiography allows selective detection of histamine H3 receptor-dependent G protein activation in rat brain tissue sections. Laitinen JT; Jokinen M J Neurochem; 1998 Aug; 71(2):808-16. PubMed ID: 9681473 [TBL] [Abstract][Full Text] [Related]
43. Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H(3)-receptor antagonists. Grassmann S; Sadek B; Ligneau X; Elz S; Ganellin CR; Arrang JM; Schwartz JC; Stark H; Schunack W Eur J Pharm Sci; 2002 May; 15(4):367-78. PubMed ID: 11988398 [TBL] [Abstract][Full Text] [Related]
44. N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. Kitbunnadaj R; Hashimoto T; Poli E; Zuiderveld OP; Menozzi A; Hidaka R; de Esch IJ; Bakker RA; Menge WM; Yamatodani A; Coruzzi G; Timmerman H; Leurs R J Med Chem; 2005 Mar; 48(6):2100-7. PubMed ID: 15771452 [TBL] [Abstract][Full Text] [Related]
45. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles. Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364 [TBL] [Abstract][Full Text] [Related]
46. Ligands of the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type. Plazzi PV; Mor M; Bordi F; Silva C; Rivara S; Caretta A; Ballabeni V; Impicciatore M; Vitali T Farmaco; 1997 May; 52(5):295-302. PubMed ID: 9274000 [TBL] [Abstract][Full Text] [Related]
47. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures. Siehler S; Nunn C; Zupanc GK; Hoyer D Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149 [TBL] [Abstract][Full Text] [Related]
48. Functional coupling between metabotropic glutamate receptors and G-proteins in rat cerebral cortex assessed by guanosine-5'-O-(3-[(35)S]thio)triphosphate binding assay. Odagaki Y; Kinoshita M; Toyoshima R Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):175-85. PubMed ID: 21443596 [TBL] [Abstract][Full Text] [Related]
49. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor. Stark H; Purand K; Hüls A; Ligneau X; Garbarg M; Schwartz JC; Schunack W J Med Chem; 1996 Mar; 39(6):1220-6. PubMed ID: 8632428 [TBL] [Abstract][Full Text] [Related]
50. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. Garbarg M; Arrang JM; Rouleau A; Ligneau X; Tuong MD; Schwartz JC; Ganellin CR J Pharmacol Exp Ther; 1992 Oct; 263(1):304-10. PubMed ID: 1383495 [TBL] [Abstract][Full Text] [Related]
51. Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor. Yao BB; Witte DG; Miller TR; Carr TL; Kang CH; Cassar S; Faghih R; Bennani YL; Surber BW; Hancock AA; Esbenshade TA Neuropharmacology; 2006 Mar; 50(4):468-78. PubMed ID: 16316670 [TBL] [Abstract][Full Text] [Related]
52. Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure. Nickel T; Bauer U; Schlicker E; Kathmann M; Göthert M; Sasse A; Stark H; Schunack W Br J Pharmacol; 2001 Apr; 132(8):1665-72. PubMed ID: 11309237 [TBL] [Abstract][Full Text] [Related]
53. In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Benavides J; Schoemaker H; Dana C; Claustre Y; Delahaye M; Prouteau M; Manoury P; Allen J; Scatton B; Langer SZ Arzneimittelforschung; 1995 May; 45(5):551-8. PubMed ID: 7612054 [TBL] [Abstract][Full Text] [Related]
54. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. Cowart M; Gfesser GA; Browman KE; Faghih R; Miller TR; Milicic I; Baranowski JL; Krueger KM; Witte DG; Molesky AL; Komater VA; Buckley MJ; Diaz GJ; Gagne GD; Zhou D; Deng X; Pan L; Roberts EM; Diehl MS; Wetter JM; Marsh KC; Fox GB; Brioni JD; Esbenshade TA; Hancock AA Biochem Pharmacol; 2007 Apr; 73(8):1243-55. PubMed ID: 17371699 [TBL] [Abstract][Full Text] [Related]
55. CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. Raddatz R; Hudkins RL; Mathiasen JR; Gruner JA; Flood DG; Aimone LD; Le S; Schaffhauser H; Duzic E; Gasior M; Bozyczko-Coyne D; Marino MJ; Ator MA; Bacon ER; Mallamo JP; Williams M J Pharmacol Exp Ther; 2012 Jan; 340(1):124-33. PubMed ID: 22001260 [TBL] [Abstract][Full Text] [Related]
56. Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice. Kruk M; Miszkiel J; McCreary AC; Przegaliński E; Filip M; Biała G Pharmacol Rep; 2012; 64(6):1316-25. PubMed ID: 23406742 [TBL] [Abstract][Full Text] [Related]